Trials / Completed
CompletedNCT00955045
A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy
A Long-Term, Multicenter, Open-Label, Safety Study With a Flexible Dose Range of KW-6002 as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Kyowa Kirin, Inc. · Industry
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study was to establish the long-term tolerability and safety of istradefylline treatment in subjects with Parkinson's disease treated with levodopa/carbidopa. In addition, treatment response and maintenance of response were assessed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | istradefylline |
Timeline
- Start date
- 2002-08-01
- Primary completion
- 2003-10-01
- Completion
- 2003-10-01
- First posted
- 2009-08-07
- Last updated
- 2024-04-25
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00955045. Inclusion in this directory is not an endorsement.